TY - JOUR
T1 - Anagrelide in Essential Thrombocythemia (ET)
T2 - Results from 150 patients over 25 years by the “Ph1-negative Myeloproliferative Neoplasms Latium Group”
AU - Mazzucconi, Maria Gabriella
AU - Baldacci, Ermina
AU - Latagliata, Roberto
AU - Breccia, Massimo
AU - Paoloni, Francesca
AU - Di Veroli, Ambra
AU - Cedrone, Michele
AU - Anaclerico, Barbara
AU - Villivà, Nicoletta
AU - Porrini, Raffaele
AU - Montefusco, Enrico
AU - Andriani, Alessandro
AU - Montanaro, Marco
AU - Scaramucci, Laura
AU - Spadea, Antonio
AU - Rago, Angela
AU - Cimino, Giuseppe
AU - Spirito, Francesca
AU - Santoro, Cristina
N1 - Funding Information:
This study was conducted with an unconditioned grant by Shire/Takeda.
Publisher Copyright:
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Background and aims: Anagrelide is a drug effective in reducing platelet counts in essential thrombocythemia (ET) and Ph1-negative myeloproliferative neoplasms. The aim of this study was to evaluate the real-life use of anagrelide in patients with ET followed over 25 years at the Haematological Institutes belonging to “Ph1-negative Myeloproliferative Neoplasms Latium Group.”. Patients and methods: Eligibility criteria were diagnosis of ET and treatment with anagrelide. Data were collected through an ad hoc case report form. Results: One hundred and fifty patients received anagrelide for a median time of 7.4 years (0.1-23.2). Anagrelide was administered as first-line therapy in 34.7% of patients, as second-line in 52% and as third-line in 13.3%: 85.4% responded to therapy. Sixty-eight/136 evaluable patients reported side effects: palpitations, peripheral vasodilation, anaemia, diarrhoea and gastric distress. Fourteen thrombotic (arterial 10, venous 4) and 51 bleeding events (minor 48, major 3) occurred. Sixteen/150 (10.6%) patients developed secondary myelofibrosis and 3/150 (2%) an acute myeloid leukaemia. Conclusions: In our experience, anagrelide is an effective drug in reducing platelet levels in a high percentage of patients with ET. It is especially addressed to younger people. A careful assessment of the thrombotic risk and monitoring of cardiac function, at diagnosis and during follow-up, is mandatory.
AB - Background and aims: Anagrelide is a drug effective in reducing platelet counts in essential thrombocythemia (ET) and Ph1-negative myeloproliferative neoplasms. The aim of this study was to evaluate the real-life use of anagrelide in patients with ET followed over 25 years at the Haematological Institutes belonging to “Ph1-negative Myeloproliferative Neoplasms Latium Group.”. Patients and methods: Eligibility criteria were diagnosis of ET and treatment with anagrelide. Data were collected through an ad hoc case report form. Results: One hundred and fifty patients received anagrelide for a median time of 7.4 years (0.1-23.2). Anagrelide was administered as first-line therapy in 34.7% of patients, as second-line in 52% and as third-line in 13.3%: 85.4% responded to therapy. Sixty-eight/136 evaluable patients reported side effects: palpitations, peripheral vasodilation, anaemia, diarrhoea and gastric distress. Fourteen thrombotic (arterial 10, venous 4) and 51 bleeding events (minor 48, major 3) occurred. Sixteen/150 (10.6%) patients developed secondary myelofibrosis and 3/150 (2%) an acute myeloid leukaemia. Conclusions: In our experience, anagrelide is an effective drug in reducing platelet levels in a high percentage of patients with ET. It is especially addressed to younger people. A careful assessment of the thrombotic risk and monitoring of cardiac function, at diagnosis and during follow-up, is mandatory.
KW - adverse events
KW - anagrelide
KW - essential thrombocythemia
KW - haemorrhage
KW - thrombosis
UR - http://www.scopus.com/inward/record.url?scp=85088320596&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088320596&partnerID=8YFLogxK
U2 - 10.1111/ejh.13454
DO - 10.1111/ejh.13454
M3 - Article
C2 - 32441419
AN - SCOPUS:85088320596
VL - 105
SP - 335
EP - 343
JO - European Journal of Haematology
JF - European Journal of Haematology
SN - 0902-4441
IS - 3
ER -